Cancer Immunology and Immunotherapy
Glenn Dranoff
Π°ΠΏΡ. 2011β―Π³. Β· Current Topics in Microbiology and Immunology ΠΠ½ΠΈΠ³Π° 344 Β· Springer Science & Business Media
5,0star
2 ΡΠ΅ΡΠ΅Π½Π·ΠΈΠΈreport
Π-ΠΊΠ½ΠΈΠ³Π°
306
Π‘ΡΡΠ°Π½ΠΈΡΠΈ
reportΠΡΠ΅Π½ΠΈΡΠ΅ ΠΈ ΡΠ΅ΡΠ΅Π½Π·ΠΈΠΈΡΠ΅ Π½Π΅ ΡΠ΅ ΠΏΠΎΡΠ²ΡΠ΄Π΅Π½ΠΈ Β ΠΠΎΠ·Π½Π°ΡΡΠ΅ ΠΏΠΎΠ²Π΅ΡΠ΅
ΠΠ° Π΅-ΠΊΠ½ΠΈΠ³Π°Π²Π°
The interplay between tumors and their immunologic microenvironment is complex, difficult to decipher, but its understanding is of seminal importance for the development of novel prognostic markers and therapeutic strategies. The present review discusses tumor-immune interactions in several human cancers that illustrate various aspects of this complexity and proposes an integrated scheme of the impact of local immune reactions on clinical outcome. Current active immunotherapy trials have shown durable tumor regressions in a fraction of patients. However, clinical efficacy of current vaccines is limited, possibly because tumors skew the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs), all of which prevent the generation of effector cells. To improve the clinical efficacy of cancer vaccines in patients with metastatic disease, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of the immunosuppressive tumor microenvironment.
ΠΡΠ΅Π½ΠΈ ΠΈ ΡΠ΅ΡΠ΅Π½Π·ΠΈΠΈ
5,0
2 ΡΠ΅ΡΠ΅Π½Π·ΠΈΠΈ
ΠΡΠ΅Π½Π΅ΡΠ΅ ΡΠ° Π΅-ΠΊΠ½ΠΈΠ³Π°Π²Π°
ΠΠ°ΠΆΠ΅ΡΠ΅ Π½ΠΈ ΡΡΠΎ ΠΌΠΈΡΠ»ΠΈΡΠ΅.
ΠΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΈ Π·Π° ΡΠΈΡΠ°ΡΠ΅
ΠΠ°ΠΌΠ΅ΡΠ½ΠΈ ΡΠ΅Π»Π΅ΡΠΎΠ½ΠΈ ΠΈ ΡΠ°Π±Π»Π΅ΡΠΈ
ΠΠ½ΡΡΠ°Π»ΠΈΡΠ°ΡΡΠ΅ ΡΠ° Π°ΠΏΠ»ΠΈΠΊΠ°ΡΠΈΡΠ°ΡΠ° Google Play Books Π·Π° Android ΠΈ iPad/iPhone. ΠΠ²ΡΠΎΠΌΠ°ΡΡΠΊΠΈ ΡΠ΅ ΡΠΈΠ½Ρ
ΡΠΎΠ½ΠΈΠ·ΠΈΡΠ° ΡΠΎ ΡΠΌΠ΅ΡΠΊΠ°ΡΠ° ΠΈ Π²ΠΈ ΠΎΠ²ΠΎΠ·ΠΌΠΎΠΆΡΠ²Π° Π΄Π° ΡΠΈΡΠ°ΡΠ΅ ΠΎΠ½Π»Π°ΡΠ½ ΠΈΠ»ΠΈ ΠΎΡΠ»Π°ΡΠ½ ΠΊΠ°Π΄Π΅ ΠΈ Π΄Π° ΡΡΠ΅.
ΠΠ°ΠΏΡΠΎΠΏΠΈ ΠΈ ΠΊΠΎΠΌΠΏΡΡΡΠ΅ΡΠΈ
ΠΠΎΠΆΠ΅ Π΄Π° ΡΠ»ΡΡΠ°ΡΠ΅ Π°ΡΠ΄ΠΈΠΎΠΊΠ½ΠΈΠ³ΠΈ ΠΊΡΠΏΠ΅Π½ΠΈ ΠΎΠ΄ Google Play ΡΠΎ ΠΊΠΎΡΠΈΡΡΠ΅ΡΠ΅ Π½Π° Π²Π΅Π±-ΠΏΡΠ΅Π»ΠΈΡΡΡΠ²Π°ΡΠΎΡ Π½Π° ΠΊΠΎΠΌΠΏΡΡΡΠ΅ΡΠΎΡ.
Π-ΡΠΈΡΠ°ΡΠΈ ΠΈ Π΄ΡΡΠ³ΠΈ ΡΡΠ΅Π΄ΠΈ
ΠΠ° Π΄Π° ΡΠΈΡΠ°ΡΠ΅ Π½Π° ΡΡΠ΅Π΄ΠΈ ΡΠΎ Π΅-ΠΌΠ°ΡΡΠΈΠ»ΠΎ, ΠΊΠ°ΠΊΠΎ ΡΡΠΎ ΡΠ΅ Π΅-ΡΠΈΡΠ°ΡΠΈΡΠ΅ Kobo, ΡΠ΅ ΡΡΠ΅Π±Π° Π΄Π° ΠΏΡΠ΅Π·Π΅ΠΌΠ΅ΡΠ΅ Π΄Π°ΡΠΎΡΠ΅ΠΊΠ° ΠΈ Π΄Π° ΡΠ° ΠΏΡΠ΅ΡΡΠ»ΠΈΡΠ΅ Π½Π° ΡΡΠ΅Π΄ΠΎΡ. Π‘Π»Π΅Π΄Π΅ΡΠ΅ Π³ΠΈ Π΄Π΅ΡΠ°Π»Π½ΠΈΡΠ΅ ΡΠΏΠ°ΡΡΡΠ²Π° Π²ΠΎ Π¦Π΅Π½ΡΠ°ΡΠΎΡ Π·Π° ΠΏΠΎΠΌΠΎΡ Π·Π° ΠΏΡΠ΅ΡΡΠ»Π°ΡΠ΅ Π½Π° Π΄Π°ΡΠΎΡΠ΅ΠΊΠΈΡΠ΅ Π½Π° ΠΏΠΎΠ΄Π΄ΡΠΆΠ°Π½ΠΈ Π΅-ΡΠΈΡΠ°ΡΠΈ.
